AaproM.S., AlbertD.S, SalmonS.E.: Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clogenic assay. Cancer Chemother. Pharmacol., 10; 161 (1983).
2.
CreaganE.T., BucknerJ.C., HanhR.G., RichardsonR.R., SchaidD.J., KovachJ.S.: An evaluation of recombinant leukocyte and interferon with aspirin in patients with renal cell cancer. Cancer, 61; 1787–1791 (1988).
3.
deKernionJ.B., RamringK.B., SmithR.B.: The natural history of metastatic renal cell carcinoma: a computer analysis. J. Urol., 121; 641–659 (1979).
4.
deKernionJ.B., LindnerA.: Treatment of advanced cell carcinoma. Proceed. First Intern. Symposium on Kidney Tumors.LissAlan R., 641–659, New York 1979.
5.
FiglinR.A., deKernionJ.B., MaldazysJ., JarnagA.: Treatment of renal cell carcinoma with human leukocyte and interferon vinblastine combination: a phase I-II trial. Cancer Treat. Rep., 69; 263 (1984).
6.
FisherR.J., ColtmanC.A., DoroshowJ.H.: Metastatic renal cell cancer treated with interleukin-2 and lymphokine activated killer cells. Amer. Intern. Med., 108; 518–523 (1988).
7.
HrusheskyW.J., MurphyG.P.: Current status of the therapy of advanced renal carcinoma. J. Surg. Oncol., 9; 277–278 (1977).
8.
KirkwoodJ.M., HarrisJ.E., VeraR.: A randomized study of low and high doses of leukocyte alpha-interferon in metastatic cell carcinoma. Amer. Cancer Soc. Collaborative Trial. Cancer Res., 45; 8763–871 (1985).
9.
KirkwoodJ.M., ErnstoffM.S.: Interferons in the treatment of human cancer. J. Clinc. Oncol., 2; 336–352 (1984).
OliverR.T.D., NethersellA.B.W., BottomleyJ.M.: Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Brit. J. Urol., 63; 128–131 (1989).
12.
QuesadàJ.M., RiosA., SwansonD., TrownP., GuttermannJ.V.: Antitumor activity of recombinant derived interferon in metastatic renal cell carcinoma. J. Clin. Oncol., 3; 1522–1628 (1985).
13.
RamaniP., HartI.R., BalkvillF.R.: The effect of interferon on experimental metastasis in immunocompetent and immunodeficient mice. Intern. J. Cancer, 37; 363–368 (1986).
14.
RosenbergS.A., LotzeM.T., MuulL.M.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine actived killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med., 316; 889–897 (1987).
15.
TortiF.M., LumB.L.: The biology and treatment of superficial bladder cancer. J. Clin. Oncol., 2; 505–531 (1984).
16.
WestW.H., TauerK.W., YannelliJ.R.: Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. Ñ. Engl. J. Med., 316; 898–905 (1987).
